Jill Lopez 7/31/25 Jill Lopez 7/31/25

FDA Gives Conditional Green Light to First-Ever Drug for Subclinical HCM in Cats: Felycin®-CA1 Now Available to Veterinarians

Felycin®-CA1 becomes the first and only FDA-conditionally approved drug for managing subclinical hypertrophic cardiomyopathy (HCM) in cats. Learn how it’s changing feline cardiac care.

Jill Lopez 5/5/25 Jill Lopez 5/5/25

PBI-Gordon Companies Acquires TriviumVet, Expanding Portfolio of Innovative Treatments in Pet Health

PBI-Gordon Companies, Inc., an organization that inspires innovations for green spaces, pets, and people, announces the strategic acquisition of TriviumVet®, a leading research and development company advancing innovative treatments for chronic conditions in cats and dogs. The move is the largest transaction in the company's 77-year history and includes the addition of an innovative new product, Felycin®-CA1, to the PRN® Pharmacal portfolio of products.